The FDA has approved the first and so far only pharmacological treatment for presbyopia, a sight condition that typically starts in middle age and involves difficulty in focusing on near ob
Merck & Co has signed a licensing deal with the UN-backed Medicines Patent Pool (MPP) that could pave the way for generic companies to manufacture its much-anticipated oral antiviral fo
Eli Lilly has followed through on its plan to file for approval of its Alzheimer's disease candidate donanemab, and is planning to take on Biogen and Eisai with a head-to-head trial against
NICE has decided not to recommend Seagen's orally-active HER2 inhibitor Tukysa for advanced breast cancer in draft guidance, saying it isn't a cost-effective use of NHS resources.<
The EMA has started a rolling review of Merck & Co and Ridgeback Biotherapeutics' much-anticipated oral antiviral molnupiravir as a treatment for COVID-19 in adults.
Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular inj